Research2025 · First-author AAPM poster

Choosing a beam means choosing a tradeoff.

AAPM 2025 poster comparing 6X-FFF and 10X-FFF for lung SBRT
Original AAPM 2025 lung SBRT beam-energy poster · Source

Beam energy affects more than delivery speed. This planning-and-phantom study asks how the choice between two flattening-filter-free photon beams changes lung-treatment dosimetry and efficiency.

Dosimetry and delivery efficiency of 6X-FFF versus 10X-FFF for lung SBRT
Original public recordings

Watch the study.

Preview images load from this site. YouTube connects only after you press play.

Research · 9:14

Dosimetric Comparison of 6X/10X flattening filter free beams at the Juravinski Cancer Centre

The final thesis presentation comparing 6X and 10X flattening-filter-free beams at Juravinski Cancer Centre.

Uploaded April 17, 2025
Event: April 16, 2025

The question

Stereotactic body radiotherapy (SBRT) delivers highly focused treatment outside the brain. For lung targets, the surrounding anatomy and the target’s location can influence which beam characteristics are useful.

This work compared 6X-FFF and 10X-FFF beams, two flattening-filter-free photon-beam options, in Eclipse treatment planning and delivery measurements.

From plan to phantom

The evaluation included a custom heterogeneous lung phantom made from cork and acrylic. A phantom allows a physical measurement to complement the computer-generated dose plan.

The work was presented as a first-author AAPM 2025 poster with Carlos E. Cardenas and Marcin Wierzbicki.

What the comparison showed

The reported central-tumour organ-at-risk sparing favored 6X-FFF. Peripheral skin-dose and delivery-time measures favored 10X-FFF; mean delivery times were 72.3 and 43.1 seconds, respectively.

These are configuration-dependent planning and phantom findings. They do not establish one universally preferable beam energy or demonstrate a patient-outcome benefit.

Sources & further reading

Research summary updated October 5, 2026. Findings describe the linked study and do not establish clinical readiness beyond its evaluation.